Indoleamine 2, 3-dioxygenase (IDO): Biology and target in cancer immunotherapies
Document Type
Journal Article
Publication Date
11-1-2016
Journal
Current Cancer Drug Targets
Volume
16
Issue
9
DOI
10.2174/1568009615666151030102250
Keywords
3-dioxygenase (IDO); Cancer immunotherapy; Combination therapy; IDO inhibitors; Immune tolerance; Indoleamine 2
Abstract
© 2016 Bentham Science Publishers. Indoleamine 2, 3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.
APA Citation
Selvan, S., Dowling, J., Kelly, W., & Lin, J. (2016). Indoleamine 2, 3-dioxygenase (IDO): Biology and target in cancer immunotherapies. Current Cancer Drug Targets, 16 (9). http://dx.doi.org/10.2174/1568009615666151030102250
